BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 11012560)

  • 1. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
    Martin RM; Dunn NR; Freemantle S; Shakir S
    Br J Clin Pharmacol; 2000 Oct; 50(4):366-72. PubMed ID: 11012560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
    Labenz J; Petersen KU; Rösch W; Koelz HR
    Aliment Pharmacol Ther; 2003 Apr; 17(8):1015-9. PubMed ID: 12694083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England.
    Wilton LV; Key C; Shakir SA
    Drug Saf; 2003; 26(2):121-32. PubMed ID: 12534328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.
    Brunner G; Athmann C; Boldt JH
    Dig Dis Sci; 2001 May; 46(5):993-6. PubMed ID: 11341670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of proton pump inhibitors--an overview.
    Arnold R
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():65-70. PubMed ID: 8180297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton-pump inhibitors: three of a kind?
    Bateman DN
    Lancet; 1997 Jun; 349(9066):1637-8. PubMed ID: 9186377
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
    Andersson T; Holmberg J; Röhss K; Walan A
    Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
    Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline.
    Pan WJ; Goldwater DR; Zhang Y; Pilmer BL; Hunt RH
    Aliment Pharmacol Ther; 2000 Mar; 14(3):345-52. PubMed ID: 10735929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
    Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
    World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
    Leonhardt U; Ritzel U; Ramadori G
    Internist (Berl); 1996 Sep; 37(9):944-9; discussion 949. PubMed ID: 8964694
    [No Abstract]   [Full Text] [Related]  

  • 13. Proton pump inhibitors: a study of GPs' prescribing.
    Jones MI; Greenfield SM; Jowett S; Bradley CP; Seal R
    Fam Pract; 2001 Jun; 18(3):333-8. PubMed ID: 11356744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apparent anaphylaxis associated with pantoprazole.
    Gratacós L; Soy D; Lluís M; López B; Nicolás JM; Codina C; Nogué S; Ribas J
    Am J Health Syst Pharm; 2005 Jul; 62(13):1388-9. PubMed ID: 15972383
    [No Abstract]   [Full Text] [Related]  

  • 15. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
    Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
    Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline.
    Dilger K; Zheng Z; Klotz U
    Br J Clin Pharmacol; 1999 Sep; 48(3):438-44. PubMed ID: 10510158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective follow-up study of 5669 users of lansoprazole in daily practice.
    Leufkens H; Claessens A; Heerdink E; van Eijk J; Lamers CB
    Aliment Pharmacol Ther; 1997 Oct; 11(5):887-97. PubMed ID: 9354197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of proton pump inhibitors on thyroid hormone metabolism in rats: a comparison of UDP-glucuronyltransferase induction.
    Masubuchi N; Hakusui H; Okazaki O
    Biochem Pharmacol; 1997 Dec; 54(11):1225-31. PubMed ID: 9416973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lichenoid drug eruption with proton pump inhibitors.
    Bong JL; Lucke TW; Douglas WS
    BMJ; 2000 Jan; 320(7230):283. PubMed ID: 10650025
    [No Abstract]   [Full Text] [Related]  

  • 20. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
    Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.